No summary available
No summary available
The harm reduction toolkit was recently updated by AAPP member Michelle Geier. Content focuses on defining harm reduction, harm reduction services for individuals and communities, and the identification of potential barriers to pharmacist engagement in harm reduction practices. AAPP members receive complimentary, continuous access to toolkits. Non-members can purchase for a fee for a period of 3 months.
No summary available
No summary available
HHS and the Department of Veterans Affairs operate three major national support hotlines: the 988 Suicide & Crisis Lifeline (988 Lifeline), the Veterans Crisis Line, and the National Maternal Mental Health Hotline. According to a recent Government Accountability Office report covering fiscal year 2025, overall contact volume across all three hotlines generally increased throughout the year.
JAMA Psychiatry article that evaluated racial and ethnic disparities in retention in buprenorphine and methadone treatment among pregnant US females with OUD.
This living umbrella review synthesized and evaluated the certainty of all available meta-analytic evidence on treatments for bipolar disorder across age groups, mood phases, and outcomes.
New SAMHSA Publication! This policy paper presents current evidence on AI and mental health services, and examines what is known or proposed in a rapidly evolving AI enterprise. Based on this information, the paper provides considerations for policymakers as they govern responsibly advancing AI into mental health and substance use disorder services.
Findings from this study suggest that Oregon’s state-regulated psilocybin services are generally safe and associated with improvements in mental health symptoms.
AAPP submitted comments on CMS’s CY 2027 Hospital Outpatient Prospective Payment System (OPPS) proposed rule, supporting CMS’s proposed updates to payment rates for Intensive Outpatient Programs (IOPs) and Partial Hospitalization Programs (PHPs) by using the most recent available claims and cost data.
The CMS Healthcare Advisory Committee (HAC) is charged with developing recommendations to improve the U.S. healthcare system, including addressing healthcare access and workforce challenges. In preparation for its next meeting, AAPP submitted comments urging the HAC to support policies that allow for greater use of psychiatric pharmacists to help address behavioral health workforce shortages and expand access to mental health and substance use disorder care.
ASAM is recruiting experts to help develop updated clinical guidance on integrating tobacco use disorder interventions into addiction treatment. Opportunities are available on the writing group, education faculty team, and as field reviewers. Applications are due August 12.
Fewer adolescents reported using tobacco, alcohol, marijuana, and binge drinking.
Risks rose through year 5 in youths, but were seen after even just 1 year.
Triple reuptake inhibitor centanafadine is indicated for patients ages 6 years and older.
Families desperately need support too.
This study of US youths found that year-to-year elevations in self-reported PSMU were directly associated with ADHD symptoms during mid-adolescence, particularly among males; reverse associations of ADHD symptoms with later PSMU were small in magnitude and sporadic.
This PhenX Toolkit SURWG process resulted in a new Substance Use Recovery Specialty Collection of recommended protocols with specific multidimensional applicability.
By gaining an understanding of the populations benefiting from these services, breadth of services provided, and the costs required to address this barrier to care, we may more effectively inform decision-makers on the resources needed to link and retain individuals in treatment.
This study illuminated reasons for not carrying naloxone, primarily related to stigma, discomfort with administration, or a lack of awareness/risk perception for an opioid-related overdose.
This study found no evidence any individual route of administration was associated with higher heroin overdose risk; instead, use of a single route tended to be associated with lower overdose odds than use of multiple routes.
Results suggest acceptability of a device for overdose detection and naloxone administration among PWUO and the addiction workforce, with more acceptability for a wearable versus implantable device.
In this study of pharmacies across the US, same-day naloxone availability and price remained uneven following OTC approval.
Among adults with AUD and T2D or obesity, initiation of newer GLP-1 RAs was associated with a lower observed risk of alcohol-related hospitalisation.
This paper briefly outlines the scientific rationale for brain circuit–based care, reviews the evidence for key interventions, and identifies barriers to implementation within public systems.